Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.

Publication Type:

Journal Article


British journal of haematology, Volume 151, Issue 5, p.430-4 (2010)


2010, Adenine Nucleotides, Adult, Antineoplastic Combined Chemotherapy Protocols, Arabinonucleosides, Center-Authored Paper, Clinical Research Division, Connective Tissue Growth Factor, Cytarabine, Female, Humans, Male, Neoplasm Proteins, Nucleoside Transport Proteins, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Public Health Sciences Division, RECURRENCE, Shared Resources, Specimen Processing Core Facility, Treatment Outcome


Clofarabine and cytarabine target different steps in DNA synthesis and replication, are synergistic in vivo, and have non-overlapping toxicities, making this combination a potentially promising treatment for acute lymphocytic leukaemia. Thirty-seven patients were treated. The median age was 41 years, 44% of patients were either in ≥2nd relapse or had refractory disease and 59% of patients had poor risk cytogenetics. Six out of 36 patients (17%) achieved a complete remission with or without complete count recovery; median overall survival was 3 months. Nucleoside transporter expression did not predict outcome. This regimen lacked sufficient activity to warrant further testing.